8-K Announcements
6Material company update
May 19, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Mar 27, 2026·SEC
Rapid Micro Biosystems, Inc.(RPID)Earnings, Financials & Key Ratios
RPID•NASDAQ
$1.77
Price updated Jul 6, 2026
AboutRapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.Show more
- Revenue$34M+19.7%
- EBITDA-$44M+5.2%
- Net Income-$47M-0.5%
- EPS (Diluted)-1.05+2.8%
- Gross Margin22.65%+5929.0%
- EBITDA Margin-131.42%+20.8%
- Operating Margin-141.1%+20.7%
- Net Margin-140.3%+16.1%
- ROE-86.82%-79.0%
RPID Price & Volume
Rapid Micro Biosystems, Inc. (RPID) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Capital Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital exhaustion
Key Thesis Takeaways
- Rapid Micro Biosystems faces a precarious fundamental outlook characterized by an inability to achieve operating leverage, as evidenced by a 2026Q1 operating margin of -173.1%.
- While the company attempts to scale its Growth Direct platform, the persistent disconnect between revenue and operating expenses suggests a high risk of insolvency.
- Investors should monitor the company's dwindling cash position of $13.8 million, which appears insufficient to cover the ongoing quarterly cash burn that reached $15.5 million in 2026Q1.
Verdict Logic
Negative: The company's fundamental viability is challenged by a cumulative retained earnings deficit of $536.7 million and a quarterly cash burn rate that significantly exceeds its current $13.8 million cash reserve.
RPID Growth Metrics
Rapid Micro Biosystems, Inc. (RPID) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years15.88%
3 Years25.15%
TTM15.99%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-11.84%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-7.77%
Return on Capital
10 Years-55.86%
5 Years-44.44%
3 Years-52.03%
Last Year-69.2%
RPID Recent Earnings
Rapid Micro Biosystems, Inc. (RPID) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.31-29.2%
$0.24
Rev
$8M+5.3%
$8M
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.28-21.7%
$0.23
Rev
$11M-0.6%
$11M
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.26+0.0%
$0.26
Rev
$8M-28.3%
$11M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.27-3.8%
$0.26
Rev
$7M-12.9%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.31vs $0.24-29.2% | $8Mvs $8M+5.3% |
| Q2 2026 | Mar 12, 2026 | $0.28vs $0.23-21.7% | $11Mvs $11M-0.6% |
| Q4 2025 | Nov 7, 2025 | $0.26vs $0.26+0.0% | $8Mvs $11M-28.3% |
| Q3 2025 | Aug 12, 2025 | $0.27vs $0.26-3.8% | $7Mvs $8M-12.9% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Rapid Micro Biosystems, Inc. (RPID)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.77 | $80.22M | -1.69 | 19.74% | -140.3% | -86.82% | — | |
| $564.98 | $44.87B | 43.19 | 10.42% | 24.63% | 70.87% | — | |
| $9.51 | $2.07B | -1.89 | -3.2% | -69.93% | -29% | — | |
| $61.34 | $9.34B | -408.93 | 2.08% | -0.34% | -0.5% | — | |
| $25.67 | $1.18B | -21.04 | 3.55% | -29.86% | -10.69% | — | |
| $295.15 | $7.97B | 10.59 | 0.65% | 6.52% | 2.4% | — |
Compare RPID vs Peers
Rapid Micro Biosystems, Inc. (RPID) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RPID SEC Filings & Documents
Rapid Micro Biosystems, Inc. (RPID) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when RPID posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RPID Frequently Asked Questions
Rapid Micro Biosystems, Inc. (RPID) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Rapid Micro Biosystems, Inc.'s revenue?
Rapid Micro Biosystems, Inc. (RPID) reported $34.4M in revenue for fiscal year 2025. This represents a 108% increase from $16.5M in 2019.
How fast is Rapid Micro Biosystems, Inc. growing?
Rapid Micro Biosystems, Inc. (RPID) grew revenue by 19.7% over the past year. This is strong growth.
Is RPID profitable?
Rapid Micro Biosystems, Inc. (RPID) reported a net loss of $50.1M for fiscal year 2025.
Dividend & Returns
What is RPID's return on equity?
Rapid Micro Biosystems, Inc. (RPID) has a return on equity (ROE) of -86.8%. Negative ROE indicates the company is unprofitable.
What is Rapid Micro Biosystems, Inc.'s free cash flow?
Rapid Micro Biosystems, Inc. (RPID) had negative free cash flow of $37.1M in fiscal year 2025, likely due to heavy capital investments.